5 results about "Hypnotic agent" patented technology

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and / or 5-HT2A inverse agonist or antagonist.

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and / or 5-HT2A inverse agonist or antagonist.

The invention relates to administration of clinical anesthesia. Particular embodiments provide systems and methods for controlled delivery of a combination of an analgesic agent and a hypnotic agent. More specifically, the invention relates to closed-loop control systems / methods for automatically controlling the administration of a combination of a hypnotic agent and an analgesic agent in a clinical anesthesia setting which incorporate feedback based on one or more indirect measures / indicia of analgesia. The invention further relates to such control systems / methods that account for limitations of such indirect measures / indicia of analgesia.

The application belongs to the field of pharmacy, discloses a fused ring morphine derivative and a preparation method and application thereof, and relates to N-cyclopropylmethyl-4'-substituted aminonalepotem series derivatives with formula (I) and pharmaceutically acceptable salts. The derivative with formula (I) is prepared by reacting thebaine with a substituted phenyl vinyl ketone reagent and through a series of conversion methods. Among them, N-cyclopropylmethyl-(4'-benzoyl amino) nalepotem (SLL-1062) is a typical high selectivity mu opioid receptor antagonist, and can be applied to the research and development in the fields of diagnosis and treatment of opioid and other narcotic analgesic dependence, opioid drug-induced intestinal dysfunction, sedative hypnotics and acute alcohol poisoning, opioid and other narcotic analgesic poisoning and the like.

The present invention relates to a pharmaceutical composition containing an etomidate derivative, a pharmaceutically acceptable salt thereof, a prodrug thereof, or an isotope derivative thereof, and a use thereof as an anesthetic, sedative and / or hypnotic drug for animals or humans. The pharmaceutical composition is a fat emulsion injection, the encapsulation efficiency of the pharmaceutical composition is stabilized at 90% or above to 98%, the particle size is small and concentrated in distribution, the content of related substances (including acid impurities and total impurities) is lower than that of an etomidate emulsion injection, and the stability, bioavailability, safety and effectiveness of the pharmaceutical composition are better. In the aspect of clinical application, compared with etomidate, the etomidate derivative has the advantages that the clinical dosage is reduced, the anesthesia, sedation and / or hypnosis duration on animals or human beings under the condition of a relatively low dosage is longer than that of an etomidate group with a relatively high dosage, the recovery time is overall better than that of the etomidate group, the adverse reaction is obviously reduced, and the etomidate derivative has a good clinical application prospect. The problems that the etomidate anesthetic is large in dosage and large in side effect are solved, and discomfort of a patient in the treatment process can be remarkably reduced.